ASCO2013:国立台湾大学Ann-Lii Cheng将开展Regorafenib治疗进展期肝细胞癌3期试验
2013-05-20 ASCO2013 丁香园
背景: 索拉非尼用于HCC一线全身性治疗已被广为接受,但对于接受索拉非尼治疗后进展期患者目前尚无标准的治疗选择。一项开放标签2期研究提示多激酶抑制剂REG具有可接受的安全性能,且显示出对于进展期HCC患者的抗癌活性的证据(Bolondi et al. Eur J Cancer 2011; 47 [Suppl 1]: abstract 6.576):病例对照设置为26/36例患者(72%),中位肿瘤
背景: 索拉非尼用于HCC一线全身性治疗已被广为接受,但对于接受索拉非尼治疗后进展期患者目前尚无标准的治疗选择。一项开放标签2期研究提示多激酶抑制剂REG具有可接受的安全性能,且显示出对于进展期HCC患者的抗癌活性的证据(Bolondi et al. Eur J Cancer 2011; 47 [Suppl 1]: abstract 6.576):病例对照设置为26/36例患者(72%),中位肿瘤进展时间(TTP)为4.3月,中位总体生存时间为13.8个月。基于这一颇有前景的数据,研究者将开展3期试验。
方法:该项随机、双盲、安慰剂(PBO)对照、多国参与的研究(ClinicalTrials.gov identifier NCT01774344)将对REG vs PBO治疗接受索拉非尼后进展期HCC患者的有效性和耐受性进行评估(目标n=530)。入组标准包括巴塞罗那临床肝癌阶段B或C,Child-Pugh肝功能分级A、东部肿瘤协作组的性能状态(ECOG PS)评分0或1.。
入组前超过8周中止索拉非尼治疗或接受其他针对HCC的全身性治疗的患者被排除。患者按2:1比例随机分组,分别接受REG 160 mg或与之匹配的PBO OD,每循环4周,治疗1——3周;所有患者均接受最优支持治疗。治疗持续至疾病进展、患者死亡、不能耐受毒性、或患者/研究者决策停止治疗。研究药物可能被推迟或减量应用,以控制临床出现的明显药物相关的毒性作用。试验主要终点为OS,次要终点为TTP,无进展生存,肿瘤应答,以及安全性。
根据随机化分组进行分析,按地理区域(亚洲VS 其他地区),ECOG PS (0 vs 1),alfa-甲胎蛋白水平(<400 vs ≥400 ng/ml),肝外疾病(是或否),以及大血管侵犯(是或否)进行分层。此外,利用血液,血浆,以及存档组织等标本进行药物代谢动力学和生物标志物分析,以及健康相关的生活质量,并对卫生服务利用予以检测。Clinical trial information: NCT01774344。
Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial.
Abstract
Background: Sorafenib is the accepted first-line systemic therapy for HCC, but no standard option is available for patients with tumor progression following sorafenib. An open-label phase II study suggested that REG, a multikinase inhibitor, had an acceptable safety profile and showed evidence of antitumor activity in patients with progressive HCC (Bolondi et al. Eur J Cancer 2011; 47 [Suppl 1]: abstract 6.576): disease control was achieved in 26/36 patients (72%) and median time to progression (TTP) was 4.3 months; median overall survival (OS) was 13.8 months. On the basis of these promising data, a phase III trial was designed. Methods: This randomized, double-blind, placebo (PBO)-controlled, multinational study (ClinicalTrials.gov identifier NCT01774344) will assess the efficacy and tolerability of REG vs PBO in patients with HCC that has progressed following sorafenib treatment (target n=530). Inclusion criteria include Barcelona Clinic Liver Cancer stage B or C disease, Child–Pugh A liver function, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1. Patients who discontinued sorafenib ≥8 weeks before study entry or who received other previous systemic therapy for HCC will be excluded. Patients will be randomized in a 2:1 ratio to receive REG 160 mg or matching PBO OD for weeks 1–3 of each 4-week cycle; all patients will also receive best supportive care. Treatment will continue until disease progression, death, intolerable toxicity, or patient/investigator decision to stop. Doses of study drug may be delayed or reduced to manage clinically significant drug-related toxicities. The primary endpoint is OS; secondary endpoints are TTP, progression-free survival, tumor response, and safety. Analysis will be according to randomized group, stratified by geographic region (Asia vs rest of world), ECOG PS (0 vs 1), alfa-fetoprotein level (<400 vs ≥400 ng/ml), extrahepatic disease (yes vs no), and macrovascular invasion (yes vs no). In addition, blood, plasma, and archival tissue will be assessed for pharmacokinetic and biomarker analyses, and health-related quality of life and health utility will be measured. Clinical trial information: NCT01774344.
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
#肝细胞#
76
#细胞癌#
62
#ASC#
60
#进展期#
61
#Chen#
57
#Eng#
67
#3期试验#
58
#Regorafenib#
49